This is a StreetInsider.com Premium Only Page

(ORPH) –

Apr 29, 2022 07:50 AM Orphazyme (ORPH) announces update on in-court restructuring proceedings

Apr 29, 2022 07:43 AM Form 6-K Orphazyme A/S For: Apr 29

Apr 29, 2022 07:40 AM Form 6-K Orphazyme A/S For: Apr 29

Apr 29, 2022 02:46 AM Orphazyme announces update on in-court restructuring proceedings

Apr 28, 2022 10:13 AM Updated Financial Calendar for 2022

Apr 7, 2022 06:31 AM Form 6-K Orphazyme A/S For: Apr 07

Apr 7, 2022 06:08 AM Statutory restructuring plan adopted by creditors

Apr 6, 2022 09:30 AM Form 6-K Orphazyme A/S For: Apr 06

Apr 6, 2022 08:48 AM Updated Financial Calendar for 2022

Apr 6, 2022 06:40 AM Form 6-K Orphazyme A/S For: Apr 06

Apr 6, 2022 04:00 AM Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement

Apr 4, 2022 05:10 PM Form 6-K Orphazyme A/S For: Apr 04

Apr 4, 2022 01:44 PM Correction: Proposal for a statutory restructuring plan

Apr 1, 2022 06:05 AM Form 6-K Orphazyme A/S For: Mar 31

Mar 31, 2022 05:42 PM Form 15-12B Orphazyme A/S

Mar 31, 2022 05:36 PM Voluntary delisting of ADSs has become effective

Mar 31, 2022 03:17 PM Form 6-K Orphazyme A/S For: Mar 31

Mar 31, 2022 12:00 PM Proposal for a statutory restructuring plan

Mar 29, 2022 07:43 AM Form 6-K Orphazyme A/S For: Mar 29

Mar 29, 2022 07:15 AM Updated Financial Calendar for 2022

Mar 24, 2022 06:05 AM Form EFFECT Orphazyme A/S

Mar 22, 2022 07:26 AM Form 6-K Orphazyme A/S For: Mar 22

Mar 22, 2022 06:54 AM Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C

Mar 22, 2022 06:01 AM Form 6-K Orphazyme A/S For: Mar 21

Mar 21, 2022 05:45 PM Orphazyme A/S (ORPH) has filed for voluntary delisting of ADSs

Mar 21, 2022 05:44 PM Orphazyme A/S has filed for voluntary delisting of ADSs

Mar 21, 2022 04:36 PM Form S-8 POS Orphazyme A/S

Mar 21, 2022 04:33 PM Form S-8 POS Orphazyme A/S

Mar 21, 2022 04:28 PM Form POS AM Orphazyme A/S

Mar 21, 2022 04:24 PM Form 25 Orphazyme A/S

Mar 18, 2022 08:14 AM Form 6-K Orphazyme A/S For: Mar 18

Mar 18, 2022 06:40 AM Notice of in-court restructuring proceedings of Orphazyme A/S

Mar 10, 2022 05:12 PM Form 6-K Orphazyme A/S For: Mar 10

Mar 10, 2022 04:09 PM Orphazyme (ORPH) to voluntarily delist ADSs from the Nasdaq

Mar 10, 2022 04:05 PM Commencement of in-court restructuring of Orphazyme A/S

Mar 3, 2022 07:44 AM Form 6-K Orphazyme A/S For: Mar 03

Mar 3, 2022 03:35 AM Updated Financial Calender for 2022

Feb 28, 2022 06:57 AM Form 6-K Orphazyme A/S For: Feb 28

Feb 28, 2022 02:25 AM Anders Vadsholt takes over as CEO of Orphazyme

Feb 24, 2022 08:00 AM CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

Feb 24, 2022 06:27 AM Form 6-K Orphazyme A/S For: Feb 24

Feb 23, 2022 04:32 PM Orphazyme(ORPH) notified by the CHMP of a negative trend vote on the MAA for arimoclomol in NPC

Feb 23, 2022 04:05 PM Orphazyme announces update on regulatory review of arimoclomol in the European Union

Feb 18, 2022 04:13 PM Form 6-K Orphazyme A/S For: Feb 18

Feb 18, 2022 04:01 PM Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program

Feb 15, 2022 03:37 PM Form 6-K Orphazyme A/S For: Feb 15

Feb 15, 2022 12:15 PM Resolutions passed at the Extraordinary General Meeting

Feb 14, 2022 04:46 PM Form 6-K Orphazyme A/S For: Feb 14

Feb 14, 2022 04:01 PM Amendment of proposals put forward at the Extraordinary General Meeting

Feb 14, 2022 08:00 AM CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C